{"id":"https://openalex.org/W2892225166","doi":"https://doi.org/10.2217/fon-2018-0509","title":"Management of Challenging Immune-Related Gastrointestinal Adverse Events Associated with Immune Checkpoint Inhibitors","display_name":"Management of Challenging Immune-Related Gastrointestinal Adverse Events Associated with Immune Checkpoint Inhibitors","publication_year":2018,"publication_date":"2018-09-06","ids":{"openalex":"https://openalex.org/W2892225166","doi":"https://doi.org/10.2217/fon-2018-0509","mag":"2892225166","pmid":"https://pubmed.ncbi.nlm.nih.gov/30188189"},"language":"en","primary_location":{"id":"doi:10.2217/fon-2018-0509","doi":"https://doi.org/10.2217/fon-2018-0509","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fon-2018-0509","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041844936","display_name":"Yasuo Hamamoto","orcid":"https://orcid.org/0000-0002-5737-122X","observed_orcids":["https://orcid.org/0000-0002-5737-122X"]},"institutions":[{"id":"https://openalex.org/I203951103","display_name":"Keio University","ror":"https://ror.org/02kn6nx58","country_code":"JP","type":"education","lineage":["https://openalex.org/I203951103"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasuo Hamamoto","raw_affiliation_strings":["Keio Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan","Fax: +81 33 353 6247"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keio Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I203951103"]},{"raw_affiliation_string":"Fax: +81 33 353 6247","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059569040","display_name":"Natalya Shin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Natalya Shin","raw_affiliation_strings":["Research and Development Department, Division of Pharmacovigilance, Bristol-Myers Squibb K.K., Shinjuku-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research and Development Department, Division of Pharmacovigilance, Bristol-Myers Squibb K.K., Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000280626","display_name":"Tomohiro Hoshino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomohiro Hoshino","raw_affiliation_strings":["Safety Strategy 2, Safety management, Division of Pharmacovigilance, Ono Pharmaceutical Co., Ltd, Chuo-ku, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Strategy 2, Safety management, Division of Pharmacovigilance, Ono Pharmaceutical Co., Ltd, Chuo-ku, Osaka, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035900623","display_name":"Takanori Kanai\u2225","orcid":"https://orcid.org/0000-0002-1466-4532","observed_orcids":["https://orcid.org/0000-0002-1466-4532"]},"institutions":[{"id":"https://openalex.org/I203951103","display_name":"Keio University","ror":"https://ror.org/02kn6nx58","country_code":"JP","type":"education","lineage":["https://openalex.org/I203951103"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takanori Kanai","raw_affiliation_strings":["Department of Internal Medicine, Division of Gastroenterology & Hepatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Division of Gastroenterology & Hepatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I203951103"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2059,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.22777466,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"14","issue":"30","first_page":"3187","last_page":"3198"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9309999942779541},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/corticosteroid-tapering","display_name":"corticosteroid tapering","score":0.6819999814033508},{"id":"https://openalex.org/keywords/immunosuppressive-therapy","display_name":"immunosuppressive therapy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/gastroenterology-consultation","display_name":"gastroenterology consultation","score":0.8920000195503235},{"id":"https://openalex.org/keywords/endoscopy","display_name":"endoscopy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/computed-tomography","display_name":"computed tomography","score":0.8479999899864197},{"id":"https://openalex.org/keywords/adverse-event-management","display_name":"adverse event management","score":0.5609999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9303493499755859},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7926326394081116},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.571302056312561},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.5191818475723267},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.48178645968437195},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41086986660957336},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3775287866592407},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.238357275724411}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003952","descriptor_name":"Diagnostic Imaging","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019468","descriptor_name":"Disease Management","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon-2018-0509","doi":"https://doi.org/10.2217/fon-2018-0509","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fon-2018-0509","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:30188189","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30188189","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":100,"referenced_works":["https://openalex.org/W1014257459","https://openalex.org/W1526068104","https://openalex.org/W1543949018","https://openalex.org/W1584290919","https://openalex.org/W1605315445","https://openalex.org/W1948621219","https://openalex.org/W1971554504","https://openalex.org/W1979401452","https://openalex.org/W1979651049","https://openalex.org/W1979811833","https://openalex.org/W1987234856","https://openalex.org/W1994838999","https://openalex.org/W2006091295","https://openalex.org/W2010344908","https://openalex.org/W2018728466","https://openalex.org/W2032742712","https://openalex.org/W2034392291","https://openalex.org/W2061052668","https://openalex.org/W2069296584","https://openalex.org/W2070825440","https://openalex.org/W2078616035","https://openalex.org/W2095267413","https://openalex.org/W2095327463","https://openalex.org/W2097995306","https://openalex.org/W2098414192","https://openalex.org/W2104327407","https://openalex.org/W2104347254","https://openalex.org/W2106511606","https://openalex.org/W2112121482","https://openalex.org/W2123363005","https://openalex.org/W2125082756","https://openalex.org/W2128035403","https://openalex.org/W2129540272","https://openalex.org/W2143163879","https://openalex.org/W2150845293","https://openalex.org/W2152897456","https://openalex.org/W2154391127","https://openalex.org/W2155599713","https://openalex.org/W2156353875","https://openalex.org/W2158170171","https://openalex.org/W2158196601","https://openalex.org/W2164918836","https://openalex.org/W2166662937","https://openalex.org/W2167255026","https://openalex.org/W2222086386","https://openalex.org/W2227062383","https://openalex.org/W2259730793","https://openalex.org/W2265463245","https://openalex.org/W2270068936","https://openalex.org/W2312311174","https://openalex.org/W2312537119","https://openalex.org/W2314922821","https://openalex.org/W2325469667","https://openalex.org/W2328801030","https://openalex.org/W2338994579","https://openalex.org/W2347141054","https://openalex.org/W2371704730","https://openalex.org/W2395475730","https://openalex.org/W2400163437","https://openalex.org/W2418354692","https://openalex.org/W2463439384","https://openalex.org/W2467433249","https://openalex.org/W2467925070","https://openalex.org/W2480201404","https://openalex.org/W2529484692","https://openalex.org/W2530516001","https://openalex.org/W2531934133","https://openalex.org/W2550714119","https://openalex.org/W2551653151","https://openalex.org/W2562140182","https://openalex.org/W2581935274","https://openalex.org/W2586675028","https://openalex.org/W2588366403","https://openalex.org/W2594042408","https://openalex.org/W2597225995","https://openalex.org/W2605738018","https://openalex.org/W2606367731","https://openalex.org/W2607166620","https://openalex.org/W2618499299","https://openalex.org/W2622111008","https://openalex.org/W2624217133","https://openalex.org/W2624791371","https://openalex.org/W2735427761","https://openalex.org/W2735569299","https://openalex.org/W2736166064","https://openalex.org/W2750862728","https://openalex.org/W2751631062","https://openalex.org/W2753432434","https://openalex.org/W2754843476","https://openalex.org/W2761087768","https://openalex.org/W2763064222","https://openalex.org/W2768429453","https://openalex.org/W2769403436","https://openalex.org/W2782898385","https://openalex.org/W2783137027","https://openalex.org/W2783364950","https://openalex.org/W2786816161","https://openalex.org/W2794281764","https://openalex.org/W2890466450","https://openalex.org/W2993661185"],"related_works":["https://openalex.org/W4394776076","https://openalex.org/W7202158512","https://openalex.org/W4387734335","https://openalex.org/W2995906558","https://openalex.org/W3037532433","https://openalex.org/W7164903912","https://openalex.org/W2991971438","https://openalex.org/W4416624904","https://openalex.org/W7114788141","https://openalex.org/W4392303238"],"abstract_inverted_index":{"Immune-related":[0],"gastrointestinal":[1],"toxicities":[2],"(irGI)":[3],"are":[4,92],"well-known":[5],"adverse":[6],"events":[7],"(AEs)":[8],"with":[9,38],"immune":[10],"checkpoint":[11],"inhibitors.":[12],"The":[13,41],"aim":[14],"of":[15,43,49,61,75,78,83],"this":[16,44],"review":[17,45,66],"was":[18],"to":[19,26,29,111],"present":[20],"clinical":[21],"data":[22],"from":[23],"82":[24],"cases":[25,63,70],"provide":[27],"information":[28],"clinicians":[30],"who":[31],"face":[32],"real-world":[33],"challenges":[34],"among":[35],"their":[36],"patients":[37],"irGI":[39,97],"AEs.":[40],"findings":[42],"support":[46],"the":[47,50,56,76,81],"use":[48],"current":[51],"management":[52],"guidelines.":[53],"By":[54],"analyzing":[55],"treatment":[57],"courses":[58],"and":[59,88],"outcomes":[60],"all":[62],"identified,":[64],"our":[65],"recommends":[67],"that":[68],"recurrent":[69,117],"be":[71],"treated":[72],"carefully":[73],"regardless":[74],"grade":[77],"diarrhea":[79],"at":[80],"onset":[82],"events.":[84],"Earlier":[85],"gastroenterology":[86],"consultation":[87],"computed":[89],"tomography/endoscopy":[90],"diagnosis":[91],"essential,":[93],"especially":[94],"when":[95],"an":[96],"AE":[98],"recurs":[99],"or":[100],"worsens":[101],"during":[102],"steroid":[103],"tapering.":[104],"We":[105],"would":[106],"also":[107],"suggest":[108],"earlier":[109],"decision":[110],"add":[112],"immunosuppressant":[113],"agents,":[114],"particularly":[115],"for":[116],"cases.":[118]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2018-09-27T00:00:00"}